9 results on '"Haugli, Mette"'
Search Results
2. High circulating levels of the homeostatic chemokines CCL19 and CCL21 predict mortality and disease severity in Covid-19
- Author
-
Tveita, Anders, Murphy, Sarah Louise, Holter, Jan Cato, Kildal, Anders Benjamin, Michelsen, Annika E, Lerum, Tøri Vigeland, Kaarbø, Mari, Heggelund, Lars, Holten, Aleksander Rygh, Finbråten, Ane-Kristine, Müller, Karl Erik, Mathiessen, Alexander, Bøe, Simen, Fevang, Børre, Granerud, Beathe Kiland, Tonby, Kristian, Lind, Andreas, Dudman, Susanne Gjeruldsen, Henriksen, Katerina Nezvalova, Müller, Fredrik, Skjønsberg, Ole Henning, Trøseid, Marius, Barratt-Due, Andreas, Dyrhol-Riise, Anne Ma, Aukrust, Pål, Halvorsen, Bente, Dahl, Tuva Børresdatter, Ueland, Thor, Austad, Cathrine, Bogen, Mette, Hermann, Anne, Opsand, Hanne, Steinsvik, Trude, Woll, Bjørn Martin, Christensen, Erik Egeland, Eftestøl, Kristin, Hesstvedt, Liv, Jenum, Synne, Jørgensen, Marthe Jøntvedt, Landaas, Elisabeth Toverud, Nur, Sarah, Ormaasen, Vidar, Pettersen, Frank Olav, Quist-Paulsen, Else, Reikvam, Dag Henrik, Røstad, Kjerstin, Skeie, Linda, Steffensen, Anne Katrine, Stiksrud, Birgitte, Gravrok, Berit, Skogen, Vegard, Tylden, Garth Daryl, Andersen, Jan Terje, Kolderup, Anette, Kåsine, Trine, Lund-Johansen, Fridtjof, Olsen, Inge Christoffer, Skåra, Karoline Hansen, Tran, Trung, Fladeby, Cathrine, Holberg-Petersen, Mona, Johal, Simreen Kaur, Vaage, Eline Brenno, Aballi, Saad, Brynhildsen, Jorunn, Ghanima, Waleed, Halstensen, Anne Marie, Berg, Åse, Blomberg, Bjørn, Kvåle, Reidar, Langeland, Nina, Mohn, Kristin Greve Isdahl, Dalgard, Olav, Eiken, Ragnhild, Molvik, Richard Alexander, Ystrøm, Carl Magnus, Ernst, Gernot, Thoresen, Lars, Gustad, Lise Tuset, Saxhaug, Lars Mølgaard, Skei, Nina Vibeche, Hannula, Raisa, Haugli, Mette, Olsen, Roy Bjørkholt, Hoel, Hedda, Hoff, Dag Arne Lihaug, Johannessen, Asgeir, Åsheim-Hansen, Bjørn, Kittang, Bård Reikvam, Le, Lan Ai Kieu, Manotheepan, Ravinea, Nordberg, Lena Bugge, Rasmussen, Hans Schmidt, Stenvik, Grethe-Elisabeth, Thorkildsen, Ruth Foseide, Vinge, Leif Erik, Mielnik, Pawel, Skudal, Hilde, and Tholin, Birgitte
- Subjects
Inflammation ,Receptors, CCR7 ,Infectious Diseases ,Chemokine CCL21 ,SARS-CoV-2 ,Patient Acuity ,Humans ,Chemokine CCL19 ,COVID-19 ,Immunology and Allergy ,Chemokines - Abstract
Background Immune dysregulation is a major factor in the development of severe coronavirus disease 2019 (COVID-19). The homeostatic chemokines CCL19 and CCL21 have been implicated as mediators of tissue inflammation, but data on their regulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is limited. We thus investigated the levels of these chemokines in COVID-19 patients. Methods Serial blood samples were obtained from patients hospitalized with COVID-19 (n = 414). Circulating CCL19 and CCL21 levels during hospitalization and 3-month follow-up were analyzed. In vitro assays and analysis of RNAseq data from public repositories were performed to further explore possible regulatory mechanisms. Results A consistent increase in circulating levels of CCL19 and CCL21 was observed, with high levels correlating with disease severity measures, including respiratory failure, need for intensive care, and 60-day all-cause mortality. High levels of CCL21 at admission were associated with persisting impairment of pulmonary function at the 3-month follow-up. Conclusions Our findings highlight CCL19 and CCL21 as markers of immune dysregulation in COVID-19. This may reflect aberrant regulation triggered by tissue inflammation, as observed in other chronic inflammatory and autoimmune conditions. Determination of the source and regulation of these chemokines and their effects on lung tissue is warranted to further clarify their role in COVID-19. Clinical Trials Registration NCT04321616 and NCT04381819.
- Published
- 2022
3. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations
- Author
-
Vestad, Beate, Ueland, Thor, Lerum, Tøri Vigeland, Dahl, Tuva Børresdatter, Holm, Kristian, Barratt-Due, Andreas, Kåsine, Trine, Dyrhol-Riise, Anne Ma, Stiksrud, Birgitte, Tonby, Kristian, Hoel, Hedda, Olsen, Inge Christoffer, Henriksen, Katerina N., Tveita, Anders Aune, Manotheepan, Ravinea, Haugli, Mette, Eiken, Ragnhild, Berg, Åse, Halvorsen, Bente, Lekva, Tove, Ranheim, Trine, Michelsen, Annika Elisabeth, Kildal, Anders Benjamin, Johannessen, Asgeir, Thoresen, Lars, Skudal, Hilde Kristin, Kittang, Bård Reiakvam, Olsen, Roy Bjørkholt, Ystrøm, Carl Magnus, Skei, Nina Vibeche, Hannula, Raisa, Aballi, Saad, Kvåle, Reidar, Skjønsberg, Ole Henning, Aukrust, Pål, Hov, Johannes Espolin Roksund, and Trøseid, Marius
- Subjects
Inflammation ,Clinical Trials as Topic ,SARS-CoV-2 ,Post-Acute COVID-19 Syndrome ,RNA, Ribosomal, 16S ,Internal Medicine ,COVID-19 ,Humans ,microbiome ,Gastrointestinal Microbiome ,pulmonary function - Abstract
Background - Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and are related to long-term respiratory dysfunction remains unknown. Methods - Plasma was collected during hospital admission and after 3 months from the NOR-Solidarity trial (n = 181) and analyzed for markers of gut barrier dysfunction and inflammation. At the 3-month follow-up, pulmonary function was assessed by measuring the diffusing capacity of the lungs for carbon monoxide (DLCO). Rectal swabs for gut microbiota analyses were collected (n = 97) and analyzed by sequencing the 16S rRNA gene. Results - Gut microbiota diversity was reduced in COVID-19 patients with respiratory dysfunction, defined as DLCO below the lower limit of normal 3 months after hospitalization. These patients also had an altered global gut microbiota composition, with reduced relative abundance of 20 bacterial taxa and increased abundance of five taxa, including Veillonella, potentially linked to fibrosis. During hospitalization, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO2/fiO2 (P/F ratio)
- Published
- 2022
4. Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19
- Author
-
Vestad, Beate, primary, Ueland, Thor, additional, Lerum, Tøri Vigeland, additional, Børresdatter Dahl, Tuva, additional, Holm, Kristian, additional, Barratt-Due, Andreas, additional, Kåsine, Trine, additional, Dyrhol-Riise, Anne Ma, additional, Stiksrud, Birgitte, additional, Tonby, Kristian, additional, Hoel, Hedda, additional, Olsen, Inge Christoffer, additional, Henriksen, Katerina Nezvalova, additional, Tveita, Anders, additional, Manotheepan, Ravinea, additional, Haugli, Mette, additional, Eiken, Ragnhild, additional, Berg, Åse, additional, Halvorsen, Bente, additional, Lekva, Tove, additional, Ranheim, Trine, additional, Michelsen, Annika Elisabeth, additional, Kildal, Anders Benjamin, additional, Johannessen, Asgeir, additional, Thoresen, Lars, additional, Skudal, Hilde, additional, Kittang, Bård Reiakvam, additional, Bjørkholt Olsen, Roy, additional, Ystrøm, Carl Magnus, additional, Skei, Nina Vibeche, additional, Hannula, Raisa, additional, Aballi, Saad, additional, Kvåle, Reidar, additional, Skjønsberg, Ole Henning, additional, Aukrust, Pål, additional, Hov, Johannes Roksund, additional, and Trøseid, Marius, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Evaluation of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 Patients: Results from the NOR-Solidarity Randomised Trial
- Author
-
Barratt-Due, Andreas, primary, Olsen, Inge Christoffer, additional, Henriksen, Katerina Nezvalova, additional, Kåsine, Trine, additional, Lund-Johansen, Fridtjof, additional, Hoel, Hedda, additional, Holten, Aleksander Rygh, additional, Tveita, Anders, additional, Mathiessen, Alexander, additional, Haugli, Mette, additional, Eiken, Ragnhild, additional, Kildal, Anders Benjamin, additional, Berg, Åse, additional, Johannessen, Asgeir, additional, Heggelund, Lars, additional, Dahl, Tuva Børresdatter, additional, Skåra, Karoline Hansen, additional, Mielnik, Pawel, additional, Le, Lan Ai Kieu, additional, Thoresen, Lars, additional, Ernst, Gernot, additional, Hoff, Dag Arne Lihaug, additional, Skudal, Hilde, additional, Kittang, Bård Reiakvam, additional, Olsen, Roy Bjørkholt, additional, Tholin, Birgitte, additional, Ystrøm, Carl Magnus, additional, Skei, Nina Vibeche, additional, Tran, Trung, additional, Dudman, Susanne, additional, Andersen, Jan Terje, additional, Hannula, Raisa, additional, Dalgard, Olav, additional, Finbråten, Ane-Kristine, additional, Tonby, Kristian, additional, Blomberg, Bjørn, additional, Aballi, Saad, additional, Fladeby, Cathrine, additional, Steffensen, Anne, additional, Müller, Fredrik, additional, Dyrhol-Riise, Anne Ma, additional, Trøseid, Marius, additional, and Aukrust, Pål, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
- Author
-
Barratt-Due, Andreas, Olsen, Inge Christoffer, Nezvalova-Henriksen, Katerina, Kåsine, Trine, Lund-Johansen, Fridtjof, Hoel, Hedda, Holten, Aleksander Rygh, Tveita, Anders, Mathiessen, Alexander, Haugli, Mette, Eiken, Ragnhild, Kildal, Anders Benjamin, Berg, Åse, Johannessen, Asgeir, Heggelund, Lars, Dahl, Tuva Børresdatter, Skåra, Karoline Hansen, Mielnik, Pawel, Le, Lan Ai Kieu, and Thoresen, Lars
- Subjects
REMDESIVIR ,COVID-19 ,MEDICAL research ,HYDROXYCHLOROQUINE ,SARS-CoV-2 - Abstract
Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known.Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx.Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials.gov: NCT04321616).Setting: 23 hospitals in Norway.Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection.Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87).Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables.Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a marked decrease in SARS-CoV-2 load in the oropharynx during the first week overall, with similar decreases and 10-day viral loads among the remdesivir, HCQ, and SoC groups. Remdesivir and HCQ did not affect the degree of respiratory failure or inflammatory variables in plasma or serum. The lack of antiviral effect was not associated with symptom duration, level of viral load, degree of inflammation, or presence of antibodies against SARS-CoV-2 at hospital admittance.Limitation: The trial had no placebo group.Conclusion: Neither remdesivir nor HCQ affected viral clearance in hospitalized patients with COVID-19.Primary Funding Source: National Clinical Therapy Research in the Specialist Health Services, Norway. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. Neutrophil count predicts clinical outcome in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial.
- Author
-
Kåsine, Trine, Dyrhol‐Riise, Anne Ma, Barratt‐Due, Andreas, Kildal, Anders Benjamin, Olsen, Inge Christoffer, Nezvalova‐Henriksen, Katerina, Lund‐Johansen, Fridtjof, Hoel, Hedda, Holten, Aleksander Rygh, Tveita, Anders, Mathiessen, Alexander, Haugli, Mette, Eiken, Ragnhild, Berg, Åse, Johannessen, Asgeir, Heggelund, Lars, Dahl, Tuva Børresdatter, Halvorsen, Bente, Mielnik, Pawel, and Le, Lan Ai Kieu
- Subjects
COVID-19 ,HOSPITAL patients ,NEUTROPHILS ,TREATMENT effectiveness ,LEUKOCYTE count - Abstract
To the Editor: Despite numerous studies on SARS-CoV-2-induced inflammation, we still lack markers for rapid disease progression with admission to intensive care unit (ICU) or respiratory failure (RF). Both ferritin, reflecting macrophage activation, and LDH, as a general marker of cell damage, correlate with severe disease manifestations and/or unfavourable outcome in COVID-19 patients [7,8]. Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19
- Author
-
Barratt-Due, Andreas, Olsen, Inge Christoffer, Nezvalova-Henriksen, Katerina, Kåsine, Trine, Lund-Johansen, Fridtjof, Hoel, Hedda, Holten, Aleksander Rygh, Tveita, Anders, Mathiessen, Alexander, Haugli, Mette, Eiken, Ragnhild, Kildal, Anders Benjamin, Berg, Åse, Johannessen, Asgeir, Heggelund, Lars, Dahl, Tuva Børresdatter, Skåra, Karoline Hansen, Mielnik, Pawel, Le, Lan Ai Kieu, Thoresen, Lars, Ernst, Gernot, Hoff, Dag Arne Lihaug, Skudal, Hilde, Kittang, Bård Reiakvam, Olsen, Roy Bjørkholt, Tholin, Birgitte, Ystrøm, Carl Magnus, Skei, Nina Vibeche, Tran, Trung, Dudman, Susanne, Andersen, Jan Terje, Hannula, Raisa, Dalgard, Olav, Finbråten, Ane-Kristine, Tonby, Kristian, Blomberg, Bjorn, Aballi, Saad, Fladeby, Cathrine, Steffensen, Anne, Müller, Fredrik, Dyrhol-Riise, Anne Ma, Trøseid, Marius, and Aukrust, Pål
- Subjects
Inflammation ,Male ,Alanine ,Norway ,SARS-CoV-2 ,viruses ,COVID-19 ,Oropharynx ,Standard of Care ,Middle Aged ,Viral Load ,Antibodies, Viral ,Antiviral Agents ,Severity of Illness Index ,Adenosine Monophosphate ,COVID-19 Drug Treatment ,Treatment Outcome ,Cause of Death ,Humans ,Female ,Hospital Mortality ,Respiratory Insufficiency ,Biomarkers ,Original Research ,Hydroxychloroquine - Abstract
In an add-on study of the WHO Solidarity trial, Norwegian investigators examined the effect of remdesivir and hydroxychloroquine on the degree of clinical respiratory failure, on SARS-CoV-2 viral load in the oropharynx, and on levels of inflammatory variables in plasma or serum., Visual Abstract. Remdesivir and Hydroxychloroquine: Effects on SARS-CoV-2 Clearance. In an add-on study of the WHO Solidarity trial, Norwegian investigators examined the effect of remdesivir and hydroxychloroquine on the degree of clinical respiratory failure, on SARS-CoV-2 viral load in the oropharynx, and on levels of inflammatory variables in plasma or serum. Visual Abstract. Remdesivir and Hydroxychloroquine: Effects on SARS-CoV-2 Clearance. In an add-on study of the WHO Solidarity trial, Norwegian investigators examined the effect of remdesivir and hydroxychloroquine on the degree of clinical respiratory failure, on SARS-CoV-2 viral load in the oropharynx, and on levels of inflammatory variables in plasma or serum., Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known. Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx. Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials.gov: NCT04321616) Setting: 23 hospitals in Norway. Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection. Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87). Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables. Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a marked decrease in SARS-CoV-2 load in the oropharynx during the first week overall, with similar decreases and 10-day viral loads among the remdesivir, HCQ, and SoC groups. Remdesivir and HCQ did not affect the degree of respiratory failure or inflammatory variables in plasma or serum. The lack of antiviral effect was not associated with symptom duration, level of viral load, degree of inflammation, or presence of antibodies against SARS-CoV-2 at hospital admittance. Limitation: The trial had no placebo group. Conclusion: Neither remdesivir nor HCQ affected viral clearance in hospitalized patients with COVID-19. Primary Funding Source: National Clinical Therapy Research in the Specialist Health Services, Norway.
- Full Text
- View/download PDF
9. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations.
- Author
-
Vestad B, Ueland T, Lerum TV, Dahl TB, Holm K, Barratt-Due A, Kåsine T, Dyrhol-Riise AM, Stiksrud B, Tonby K, Hoel H, Olsen IC, Henriksen KN, Tveita A, Manotheepan R, Haugli M, Eiken R, Berg Å, Halvorsen B, Lekva T, Ranheim T, Michelsen AE, Kildal AB, Johannessen A, Thoresen L, Skudal H, Kittang BR, Olsen RB, Ystrøm CM, Skei NV, Hannula R, Aballi S, Kvåle R, Skjønsberg OH, Aukrust P, Hov JR, and Trøseid M
- Subjects
- Clinical Trials as Topic, Humans, Inflammation, RNA, Ribosomal, 16S genetics, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications, Gastrointestinal Microbiome
- Abstract
Background: Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and are related to long-term respiratory dysfunction remains unknown., Methods: Plasma was collected during hospital admission and after 3 months from the NOR-Solidarity trial (n = 181) and analyzed for markers of gut barrier dysfunction and inflammation. At the 3-month follow-up, pulmonary function was assessed by measuring the diffusing capacity of the lungs for carbon monoxide (DL
CO ). Rectal swabs for gut microbiota analyses were collected (n = 97) and analyzed by sequencing the 16S rRNA gene., Results: Gut microbiota diversity was reduced in COVID-19 patients with respiratory dysfunction, defined as DLCO below the lower limit of normal 3 months after hospitalization. These patients also had an altered global gut microbiota composition, with reduced relative abundance of 20 bacterial taxa and increased abundance of five taxa, including Veillonella, potentially linked to fibrosis. During hospitalization, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO2 /fiO2 (P/F ratio) <26.6 kPa. LBP levels remained elevated during and after hospitalization and were associated with low-grade inflammation and respiratory dysfunction after 3 months., Conclusion: Respiratory dysfunction after COVID-19 is associated with altered gut microbiota and persistently elevated LBP levels. Our results should be regarded as hypothesis generating, pointing to a potential gut-lung axis that should be further investigated in relation to long-term pulmonary dysfunction and long COVID., (© 2022 The Association for the Publication of the Journal of Internal Medicine.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.